NasdaqGS - Delayed Quote • USD
Inozyme Pharma, Inc. (INZY)
At close: April 18 at 4:00 PM EDT
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Douglas A. Treco Ph.D. | CEO & Chairman | 77k | -- | 1958 |
| Mr. Axel Bolte M.B.A., M.Sc. | Co-Founder, Senior Advisor & Director | 1.03M | -- | 1972 |
| Mr. Sanjay S. Subramanian M.B.A., M.S. | Senior VP, CFO & Principal Accounting Officer | 726.3k | -- | 1977 |
| Dr. Demetrios Braddock M.D., Ph.D. | Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer | -- | -- | -- |
| Dr. Matthew Winton Ph.D. | Senior VP & COO | -- | -- | 1978 |
| Dr. Soojin Kim Ph.D. | Senior VP & Chief Technical Operations Officer | -- | -- | -- |
| Dr. David Thompson M.A., M.S., Ph.D. | Senior VP, Chief Scientific Officer & Chief Development Officer | -- | -- | -- |
| Mr. Stefan Riley | Director of Investor Relations | -- | -- | -- |
| Ms. Gayle Gironda | Senior VP & Chief People Officer | -- | -- | -- |
| Dr. Yves Sabbagh Ph.D. | Chairman of Scientific Advisory Board & Senior VP | -- | -- | -- |
Inozyme Pharma, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 59
Description
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Corporate Governance
Inozyme Pharma, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 12, 2024S-8: Offering RegistrationsSee Full Filing
- Nov 13, 2023CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submissionSee Full Filing
- Nov 07, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Sep 26, 20238-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 07, 2024 - May 13, 2024
Inozyme Pharma, Inc. Earnings Call
Related Tickers
PDSB PDS Biotechnology Corporation
2.9000
+6.62%
MREO Mereo BioPharma Group plc
2.6500
+2.71%
LRMR Larimar Therapeutics, Inc.
6.38
-9.50%
XFOR X4 Pharmaceuticals, Inc.
1.2000
+0.42%
YMAB Y-mAbs Therapeutics, Inc.
15.00
-0.73%
DAWN Day One Biopharmaceuticals, Inc.
15.75
+6.06%
EWTX Edgewise Therapeutics, Inc.
15.45
-1.28%
CGEM Cullinan Therapeutics, Inc.
18.06
+1.01%
OCUL Ocular Therapeutix, Inc.
5.86
-22.69%
LVTX LAVA Therapeutics N.V.
2.8300
-3.74%